Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-09-02
2008-09-02
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S263000
Reexamination Certificate
active
11437291
ABSTRACT:
The present invention relates to crystalline forms of 5-chloro-6-{2,6-difluoro-4-[3-(methylamino)propoxy]phenyl}-N-[(1S)-2,2,2-trifluoro-1-methylethyl][1,2,4]triazolo[1,5-a]pyrimidin-7-amine salts; processes for the production thereof; pharmaceutical compositions thereof; and methods for inhibiting tumor growth therewith.
REFERENCES:
patent: 5593996 (1997-01-01), Pees et al.
patent: 5612345 (1997-03-01), Becher et al.
patent: 5750766 (1998-05-01), Krummel et al.
patent: 5756509 (1998-05-01), Pees et al.
patent: 5808066 (1998-09-01), Krummel et al.
patent: 5817663 (1998-10-01), Pees et al.
patent: 5854252 (1998-12-01), Pees et al.
patent: 5948783 (1999-09-01), Pees et al.
patent: 5955252 (1999-09-01), Goto et al.
patent: 5965561 (1999-10-01), Pees et al.
patent: 5981534 (1999-11-01), Pfrengle et al.
patent: 5985883 (1999-11-01), Pees et al.
patent: 5986135 (1999-11-01), Pfrengle et al.
patent: 5994360 (1999-11-01), Pfrengle et al.
patent: 6020338 (2000-02-01), Pfrengle et al.
patent: 6117865 (2000-09-01), Pees et al.
patent: 6117876 (2000-09-01), Pees et al.
patent: 6124301 (2000-09-01), Aven et al.
patent: 6204269 (2001-03-01), Pfrengle et al.
patent: 6242451 (2001-06-01), Pees et al.
patent: 6255309 (2001-07-01), Pees et al.
patent: 6268371 (2001-07-01), Sieverding et al.
patent: 6277856 (2001-08-01), Cotter et al.
patent: 6284762 (2001-09-01), Pfrengle et al.
patent: 6297251 (2001-10-01), Pees et al.
patent: 6387848 (2002-05-01), Aven et al.
patent: 6518275 (2003-02-01), Van Tuyl Cotter et al.
patent: 6521628 (2003-02-01), Cotter et al.
patent: 6699874 (2004-03-01), Cotter et al.
patent: 2002/0045631 (2002-04-01), Aven et al.
patent: 2002/0061882 (2002-05-01), Pees et al.
patent: 2002/0068744 (2002-06-01), Schmitt et al.
patent: 2002/0198222 (2002-12-01), Bruns et al.
patent: 2003/0055069 (2003-03-01), Pees et al.
patent: 2004/0097522 (2004-05-01), Gebauer et al.
patent: 2005/0030775 (2005-02-01), Lipcsei
patent: 2005/0090508 (2005-04-01), Zhang et al.
patent: 2005/0124635 (2005-06-01), Wu et al.
patent: 0 550 113 (1993-07-01), None
patent: 0 562 615 (1993-09-01), None
patent: 0 782 997 (1997-07-01), None
patent: 0 834 513 (1998-04-01), None
patent: 0 943 241 (1999-09-01), None
patent: 0 945 453 (1999-09-01), None
patent: 0 988 790 (2000-03-01), None
patent: 0 989 130 (2000-03-01), None
patent: 2 784 381 (2000-04-01), None
patent: WO-94/20501 (1994-09-01), None
patent: WO-98/41496 (1998-09-01), None
patent: WO-98/46607 (1998-10-01), None
patent: WO-99/41255 (1999-08-01), None
patent: WO-99/48893 (1999-09-01), None
patent: WO-00/18227 (2000-04-01), None
patent: WO-01/35738 (2001-05-01), None
patent: WO-02/02563 (2002-01-01), None
patent: WO-02/38565 (2002-05-01), None
patent: WO-02/46195 (2002-06-01), None
patent: WO-02/50077 (2002-06-01), None
patent: WO-02/067679 (2002-09-01), None
patent: WO-02/083676 (2002-10-01), None
patent: WO-03/008416 (2003-01-01), None
Berge et. al., J. Pharm. Sci. 1997, 66(1), p. 1-19.
Brittain et. al., 1999, “Effects of Pharmaceutical Processing on drug polymoprhys and solvates.”In Polymorphism in Pharmaceutical Solids, pp. 331-361.
http://www.expresspharmaonline.com/20031012/edit02.shtml (3 pages) Jul. 2007.
Byrn et al., “Solid State analysis of the active pharmaceutical ingredient in drug products”, 2003, DDT, vol. 8, No. 19, 898-905.
Bicher, et al., Anti-Cancer Drugs, 4:141-148 (1993).
Brill, J. Am. Chem. Soc., 54:2484-2487 (1932).
Chini, et al., Tetr. Lett., 35(5): 761-764 (1994).
Goldstein, et al., J. Natl. Cancer Inst., 81:116-124 (1989).
Gottesman, Ann. Rev. Med., 53:615-627 (2002).
Gottesman, et al., Nature Rev. Cancer, 2:48-58 (2002).
Hamel, et al., J. Biol. Chem., 259(4):2501-2508 (1984).
Hamel, Med. Res. Rev., 16:207-231 (1996).
Holmes, et al., J. Natl. Cancer Inst., 83(24):1797-1805 (1991).
Holton, et al., J. Am. Chem. Soc., 116(4):1597-1600 (1994).
Jones, et al., J. Chem. Soc. (B), pp. 1300-1315 (1971).
Jordan, et al., Cancer Res., 56:816-825 (1996).
Koepke, et al., J. Org. Chem., 44(15):2718-2722 (1979).
Kohn, et al., Natl. Cancer Inst., 86(1):18-24 (1994).
Kumar, J. Biol. Chem., 256(20):10435-10441 (1981).
Li, et al., Science & Medicine, Jan./Feb., pp. 38-47 (1999).
Loganzo, et al., Cancer Res. 63:1838-1845 (2003).
McGrath, et al., Biochem. Biophys. Res. Commun., 145(3):1171-1176 (1987).
McGuire, et al., Ann. Int. Med., 111(4):273-279 (1989).
Monteil, et al., J. Organomet Chem, 480:177-184 (1994).
Nicolaou, et al., Nature, 367:630-634 (1994).
Oka, et al., Tetrahedron, 54:1-20 (1998).
Rabindran, et al., Cancer Res., 58:5850-5858 (1998).
Rowinsky, et al., “Antimicrotubule Agents”,Cancer: Principles and Practice of Oncology, Chapter 19, Section 7, pp. 431-452 (2001).
Rowinsky, et al., Natl. Cancer Inst., 82(15):1247-1259 (1990).
Schiff, et al., Nature, 277-665-667 (1979).
Shen, et al., J. Boil. Chem., 261(17):7762-7770 (1986).
Wani, et al., J. Am. Chem. Soc., 93:2325-2327 (1971).
International Search Report and Written Opinion issued in PCT/US2007/011817, dated Dec. 13, 2007.
Blum David M.
Ku Mannching Sherry
Qi Fang Fang
Wu Yanzhong
Murray Jeffrey H
Wilmer Cutler Pickering Hale and Dorr LLP
Wilson James O
Wyeth Holdings Corporation
LandOfFree
Crystalline forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline forms of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3907543